, Columnist
Obesity Treatments Should Be Up to Doctors, Not Insurers
Increasing evidence shows the benefits of Wegovy and Zepbound, but too often insurers are the ones deciding who gets them.
Who’s making the choice for you?
Photographer: Getty Images
As evidence grows supporting the potential health benefits of obesity drugs like Novo Nordisk’s Wegovy and Eli Lilly & Co.’s Zepbound, so too— frustratingly — do the barriers to accessing them.
The latest obstacle is a deal between Novo Nordisk and CVS Caremark, the pharmacy benefit manager (PBM) for many of the nation’s employers. Under the agreement, Wegovy is now the preferred treatment, while Zepbound is no longer covered for most people.